Despite the elevated levels of PD-L1 in multiple myeloma cells, clinical trials examining the use of pembrolizumab as a single agent failed to demonstrate its efficacy in multiple myeloma [81,82]. This evidence concerns the gene CD274 and plasma cell myeloma.